OBJECTIVE: The purpose of the present study was to investigate the predictive power of sexual hormones and tumor markers in endometrial cancer. METHODS: A total of 135 healthy women were prospectively compared with 135 women who had histopathologically confirmed endometrial cancer. Both the groups of women were matched by age and body mass index. RESULTS: When compared with healthy controls, women with endometrial cancer had significantly higher serum levels of CA-125, CA 19-9, prolactin and thyroid-stimulating hormone, whereas significantly lower serum concentrations of alpha-fetoprotein, CA 15-3, follicle-stimulating hormone and luteinizing hormone (LH). Tumor stage correlated positively and significantly with serum levels of prolactin, CA-125 and CA 19-9 as did tumor grade with serum concentrations of LH, estradiol, prolactin and CA-125. Serum CA-125 levels >35 U/ml were found to have a sensitivity of 42.2%, specificity of 87.4%, positive-predictive value of 77.0% and negative-predictive value of 60.2%. Besides endometrial cancer could be diagnosed with 16.3% sensitivity, 100.0% specificity, 100.0% positive- and 54.4% negative-predictive values with serum prolactin levels >30 ng/ml. CONCLUSIONS: Because serum concentrations of CA-125 can be elevated in various malignancies, it is obvious that it is neither specific nor accurately diagnostic for endometrial tumors. What is more, the distinct effects of physiological factors on prolactin secretion shadow the credibility of this hormone in early diagnosis of endometrial tumors. Thus, either prolactin or CA-125 is far from being utilized as the sole entity for screening endometrial cancer. Therefore, both parameters should be regarded as the components of a biochemical screening panel that is to be developed in future.
OBJECTIVE: The purpose of the present study was to investigate the predictive power of sexual hormones and tumor markers in endometrial cancer. METHODS: A total of 135 healthy women were prospectively compared with 135 women who had histopathologically confirmed endometrial cancer. Both the groups of women were matched by age and body mass index. RESULTS: When compared with healthy controls, women with endometrial cancer had significantly higher serum levels of CA-125, CA 19-9, prolactin and thyroid-stimulating hormone, whereas significantly lower serum concentrations of alpha-fetoprotein, CA 15-3, follicle-stimulating hormone and luteinizing hormone (LH). Tumor stage correlated positively and significantly with serum levels of prolactin, CA-125 and CA 19-9 as did tumor grade with serum concentrations of LH, estradiol, prolactin and CA-125. Serum CA-125 levels >35 U/ml were found to have a sensitivity of 42.2%, specificity of 87.4%, positive-predictive value of 77.0% and negative-predictive value of 60.2%. Besides endometrial cancer could be diagnosed with 16.3% sensitivity, 100.0% specificity, 100.0% positive- and 54.4% negative-predictive values with serum prolactin levels >30 ng/ml. CONCLUSIONS: Because serum concentrations of CA-125 can be elevated in various malignancies, it is obvious that it is neither specific nor accurately diagnostic for endometrial tumors. What is more, the distinct effects of physiological factors on prolactin secretion shadow the credibility of this hormone in early diagnosis of endometrial tumors. Thus, either prolactin or CA-125 is far from being utilized as the sole entity for screening endometrial cancer. Therefore, both parameters should be regarded as the components of a biochemical screening panel that is to be developed in future.
Authors: Jingjing Zhu; Tracy A O'Mara; Duo Liu; Veronica Wendy Setiawan; Dylan Glubb; Amanda B Spurdle; Peter A Fasching; Diether Lambrechts; Daniel Buchanan; Pik Fang Kho; Linda S Cook; Christine Friedenreich; James V Lacey; Chu Chen; Nicolas Wentzensen; Immaculata De Vivo; Yan Sun; Jirong Long; Mengmeng Du; Xiao-Ou Shu; Wei Zheng; Lang Wu; Herbert Yu Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639
Authors: Adrián Ramírez-de-Arellano; Julio César Villegas-Pineda; Christian David Hernández-Silva; Ana Laura Pereira-Suárez Journal: Front Endocrinol (Lausanne) Date: 2021-10-21 Impact factor: 5.555
Authors: V Seebacher; G Hofstetter; S Polterauer; A Reinthaller; C Grimm; R Schwameis; S Taucher; A Wagener; C Marth; N Concin Journal: Br J Cancer Date: 2013-06-13 Impact factor: 7.640
Authors: Immaculata De Vivo; Jennifer Prescott; Veronica Wendy Setiawan; Sara H Olson; Nicolas Wentzensen; John Attia; Amanda Black; Louise Brinton; Chu Chen; Constance Chen; Linda S Cook; Marta Crous-Bou; Jennifer Doherty; Alison M Dunning; Douglas F Easton; Christine M Friedenreich; Montserrat Garcia-Closas; Mia M Gaudet; Christopher Haiman; Susan E Hankinson; Patricia Hartge; Brian E Henderson; Elizabeth Holliday; Pamela L Horn-Ross; David J Hunter; Loic Le Marchand; Xiaolin Liang; Jolanta Lissowska; Jirong Long; Lingeng Lu; Anthony M Magliocco; Mark McEvoy; Tracy A O'Mara; Irene Orlow; Jodie N Painter; Loreall Pooler; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Carlotta Sacerdote; Fredrick Schumacher; Rodney J Scott; Xin Sheng; Xiao-ou Shu; Amanda B Spurdle; Deborah Thompson; David Vanden Berg; Noel S Weiss; Lucy Xia; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Wei Zheng; Stephen Chanock; Peter Kraft Journal: Hum Genet Date: 2013-10-06 Impact factor: 4.132